BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Immune Pharmaceuticals CEO to Chair Biotechnology Industry Organization (BIO) International Panel "Can Israel Become the Next Biotech Startup Nation?"


4/23/2013 9:36:11 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

HERZLIYA-PITUACH, Israel, April 23, 2013 /PRNewswire/ -- Immune Pharmaceuticals Ltd. ("Immune"), a privately held Israeli company, announced today that the company's CEO Daniel Teper is the moderator of this morning's BIO International Convention breakout session "Can Israel Become the Next BioTech Startup Nation?" The panel, which will take place from 9:00 am 9:45 am CT today at the conference in Chicago, IL, USA, will bring together life science thought leaders to discuss high-tech innovation and biotech areas of opportunity. Speakers at today's session include:

Ora Dar, Head of Life Sciences Office of the Chief Science at Israeli Ministry of Industry Trade and Labor

Nissim Darvish, M.D., Ph.D., Senior Managing Director at Orbimed Advisors LLC

Nadav Kidron,CEO, Oramed Pharmaceuticals Inc.

Yaacov Michlin CEO, Yissum, the Technology Transfer Company of the Hebrew University of Jerusalem

About the Panel (Building: S101A; International Market Briefings Track)

Israel has become a model for high tech entrepreneurship. A country of 8 million people, Israel is home to a vibrant academic biomedical research sector, a global pharmaceutical company and several public biotech companies. Yet, the success of Israel's biotech sector pales in comparison to its high-tech industry. What can be learned from the Israeli Hi-tech Innovation and Entrepreneurship model and how can it be applied to biotech? Which regional partnerships can best leverage Israel's potential? What is the optimal positioning for Israeli Biotech to encourage biopharma companies and investors to step up their involvement? Complete panel information can be found here.

About Immune Pharmaceuticals Ltd.

Immune Pharmaceuticals Ltd. is an Israel and U.S.-based biopharmaceutical company focused on the treatment of inflammatory diseases and cancer. Immune licensed worldwide rights for systemic indications of bertilimumab from iCo Therapeutics (TSX: ICO) in June 2011, while iCo retained rights to all ophthalmic indications. iCo originally licensed the exclusive world-wide rights to bertilimumab in 2006 from Cambridge Antibody Technology Limited, now part of MedImmune, the global biologics research and development arm of AstraZeneca. Additionally, Immune has licensed from Yissum, the technology transfer company of the Hebrew University of Jerusalem, the injectable applications of the antibody nanoparticle conjugate technology (NanomAbsĀ®). For more information, visit www.immunepharmaceuticals.com.

SOURCE Immune Pharmaceuticals Ltd.



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES